Carisma Therapeutics (CARM) Stock Forecast, Price Target & Predictions

CARM Stock Forecast

Carisma Therapeutics stock forecast is as follows: an average price target of $6.00 (represents a 1335.75% upside from CARM’s last price of $0.42) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

CARM Price Target

The average price target for Carisma Therapeutics (CARM) is $6.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 1335.75% upside from CARM's last price of $0.42.

CARM Analyst Ratings

Buy

According to 3 Wall Street analysts, Carisma Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for CARM stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Carisma Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Apr 11, 2024	Justin Zelin	BTIG	$6.00	$1.91	214.14%	1335.75%

The latest Carisma Therapeutics stock forecast, released on Apr 11, 2024 by Justin Zelin from BTIG, set a price target of $6.00, which represents a 214.14% increase from the stock price at the time of the forecast ($1.91), and a 1335.75% increase from CARM last price ($0.42).

Carisma Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$6.00
Last Closing Price	$0.42	$0.42	$0.42
Upside/Downside	-100.00%	-100.00%	1335.75%

In the current month, the average price target of Carisma Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Carisma Therapeutics's last price of $0.42. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 30, 2024	EF Hutton		Buy	Initialise
Jun 26, 2024	BTIG	Underperform	Underperform	Hold
Jun 26, 2024	H.C. Wainwright	Buy	Buy	Hold
May 10, 2024	H.C. Wainwright	Buy	Buy	Hold
Apr 02, 2024	H.C. Wainwright	Buy	Buy	Hold
Nov 30, 2022	Zacks Investment Research		Buy	Upgrade

Carisma Therapeutics's last stock rating was published by EF Hutton on Oct 30, 2024. The company Initialise its CARM rating from "null" to "Buy".

Carisma Therapeutics Financial Forecast

Carisma Therapeutics Revenue Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Sep 21
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$3.83M	-	$3.24M	-
Avg Forecast	$7.93M	$7.55M	$7.18M	$6.83M	$6.49M	$6.18M	$5.87M	$5.59M	$5.31M	$5.05M	$4.81M	$4.57M	$3.11M	$3.04M	$7.40M	$3.13M	$5.42M	$5.47M	$3.92M	$4.40M	$2.91M	$1.19M	$1.08M	$3.73M	$533.33K
High Forecast	$9.85M	$9.37M	$8.91M	$8.47M	$8.06M	$7.66M	$7.29M	$6.93M	$6.59M	$6.27M	$5.97M	$5.67M	$3.86M	$3.78M	$9.19M	$3.88M	$6.73M	$6.78M	$3.92M	$5.46M	$3.61M	$1.47M	$1.34M	$4.63M	$533.33K
Low Forecast	$6.29M	$5.98M	$5.69M	$5.41M	$5.15M	$4.89M	$4.65M	$4.43M	$4.21M	$4.01M	$3.81M	$3.62M	$2.46M	$2.41M	$5.87M	$2.48M	$4.30M	$4.33M	$3.92M	$3.48M	$2.30M	$940.42K	$856.68K	$2.96M	$533.33K
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	1	1	2	1	1	1	1
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.22%	-	0.87%	-

Carisma Therapeutics's average Quarter revenue forecast for Dec 23 based on 2 analysts is $2.91M, with a low forecast of $2.30M, and a high forecast of $3.61M. CARM's average Quarter revenue forecast represents a -24.05% decrease compared to the company's last Quarter revenue of $3.83M (Sep 23).

Carisma Therapeutics EBITDA Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Sep 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	1	1	2	1	1	1	1
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-22.34M	-	$-22.18M	$63.12M
Avg Forecast	$-4.76M	$-4.53M	$-4.31M	$-4.10M	$-3.90M	$-3.71M	$-3.52M	$-3.35M	$-3.19M	$-3.03M	$-2.88M	$-2.74M	$-1.86M	$-1.83M	$-4.44M	$-1.88M	$-3.25M	$-3.28M	$-2.35M	$-2.64M	$-1.74M	$-712.00K	$-648.60K	$-2.24M	$-320.00K
High Forecast	$-3.77M	$-3.59M	$-3.41M	$-3.25M	$-3.09M	$-2.94M	$-2.79M	$-2.66M	$-2.53M	$-2.40M	$-2.29M	$-2.17M	$-1.48M	$-1.45M	$-3.52M	$-1.49M	$-2.58M	$-2.60M	$-2.35M	$-2.09M	$-1.38M	$-564.25K	$-514.01K	$-1.77M	$-320.00K
Low Forecast	$-5.91M	$-5.62M	$-5.34M	$-5.08M	$-4.84M	$-4.60M	$-4.37M	$-4.16M	$-3.96M	$-3.76M	$-3.58M	$-3.40M	$-2.31M	$-2.27M	$-5.51M	$-2.33M	$-4.04M	$-4.07M	$-2.35M	$-3.27M	$-2.16M	$-883.72K	$-805.03K	$-2.78M	$-320.00K
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	31.38%	-	9.91%	-197.26%

1 analysts predict CARM's average Quarter EBITDA for Mar 23 to be $-2.24M, with a high of $-1.77M and a low of $-2.78M. This is -103.55% lower than Carisma Therapeutics's previous annual EBITDA (Sep 21) of $63.12M.

Carisma Therapeutics Net Income Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Sep 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	1	1	2	1	1	1	1
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-21.40M	-	$-24.64M	$71.67M
Avg Forecast	$-6.63M	$-5.92M	$-5.45M	$-5.70M	$-6.59M	$-5.89M	$-5.42M	$-6.07M	$-7.02M	$-6.28M	$-5.78M	$-6.51M	$-7.08M	$-6.12M	$-5.14M	$-7.14M	$-7.39M	$-13.09M	$-12.30M	$-17.97M	$-22.95M	$-23.68M	$-24.79M	$-36.97M	$-58.16M
High Forecast	$-4.84M	$-4.33M	$-3.98M	$-4.16M	$-4.81M	$-4.30M	$-3.96M	$-4.44M	$-5.13M	$-4.58M	$-4.22M	$-4.75M	$-5.17M	$-4.47M	$-3.75M	$-5.21M	$-5.40M	$-9.56M	$-8.98M	$-13.12M	$-20.08M	$-17.29M	$-18.10M	$-27.00M	$-58.16M
Low Forecast	$-8.70M	$-7.78M	$-7.17M	$-7.48M	$-8.65M	$-7.73M	$-7.12M	$-7.98M	$-9.22M	$-8.25M	$-7.59M	$-8.55M	$-9.30M	$-8.04M	$-6.75M	$-9.38M	$-9.71M	$-17.19M	$-16.15M	$-23.60M	$-26.23M	$-31.10M	$-32.56M	$-48.57M	$-58.16M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.90%	-	0.67%	-1.23%

Carisma Therapeutics's average Quarter net income forecast for Mar 23 is $-36.97M, with a range of $-48.57M to $-27.00M. CARM's average Quarter net income forecast represents a -151.59% decrease compared to the company's last Quarter net income of $71.67M (Sep 21).

Carisma Therapeutics SG&A Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Sep 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	1	1	2	1	1	1	1
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$6.62M	-	$9.57M	$8.70M
Avg Forecast	$6.36M	$6.05M	$5.75M	$5.47M	$5.20M	$4.95M	$4.71M	$4.48M	$4.26M	$4.05M	$3.85M	$3.66M	$2.49M	$2.44M	$5.93M	$2.51M	$4.35M	$4.38M	$3.15M	$3.52M	$2.33M	$951.09K	$866.40K	$2.99M	$368.36K
High Forecast	$7.89M	$7.51M	$7.14M	$6.79M	$6.46M	$6.14M	$5.84M	$5.56M	$5.29M	$5.03M	$4.78M	$4.55M	$3.09M	$3.03M	$7.36M	$3.11M	$5.39M	$5.44M	$3.15M	$4.37M	$2.89M	$1.18M	$1.08M	$3.71M	$368.36K
Low Forecast	$5.04M	$4.79M	$4.56M	$4.34M	$4.12M	$3.92M	$3.73M	$3.55M	$3.37M	$3.21M	$3.05M	$2.90M	$1.97M	$1.93M	$4.70M	$1.99M	$3.44M	$3.47M	$3.15M	$2.79M	$1.85M	$753.73K	$686.61K	$2.37M	$368.36K
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.96%	-	3.20%	23.62%

Carisma Therapeutics's average Quarter SG&A projection for Dec 23 is $2.33M, based on 2 Wall Street analysts, with a range of $1.85M to $2.89M. The forecast indicates a -64.81% fall compared to CARM last annual SG&A of $6.62M (Sep 23).

Carisma Therapeutics EPS Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Sep 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	1	1	2	1	1	1	1
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.53	-	$-1.93	$7.28
Avg Forecast	$-0.16	$-0.14	$-0.13	$-0.14	$-0.16	$-0.14	$-0.13	$-0.15	$-0.17	$-0.15	$-0.14	$-0.16	$-0.17	$-0.15	$-0.12	$-0.17	$-0.18	$-0.32	$-0.30	$-0.43	$-0.55	$-0.57	$-0.60	$-0.89	$-1.40
High Forecast	$-0.12	$-0.10	$-0.10	$-0.10	$-0.12	$-0.10	$-0.10	$-0.11	$-0.12	$-0.11	$-0.10	$-0.11	$-0.12	$-0.11	$-0.09	$-0.13	$-0.13	$-0.23	$-0.22	$-0.32	$-0.48	$-0.42	$-0.44	$-0.65	$-1.40
Low Forecast	$-0.21	$-0.19	$-0.17	$-0.18	$-0.21	$-0.19	$-0.17	$-0.19	$-0.22	$-0.20	$-0.18	$-0.21	$-0.22	$-0.19	$-0.16	$-0.23	$-0.23	$-0.41	$-0.39	$-0.57	$-0.63	$-0.75	$-0.78	$-1.17	$-1.40
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.93%	-	2.17%	-5.20%

According to 1 Wall Street analysts, Carisma Therapeutics's projected average Quarter EPS for Mar 23 is $-0.89, with a low estimate of $-1.17 and a high estimate of $-0.65. This represents a -112.23% decrease compared to CARM previous annual EPS of $7.28 (Sep 21).

Carisma Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
HEPA	Hepion Pharmaceuticals	$0.52	$70.00	13361.54%	Buy
CARM	Carisma Therapeutics	$0.46	$6.00	1204.35%	Buy
CNSP	CNS Pharmaceuticals	$0.11	$0.50	354.55%
ZURA	Zura Bio	$2.51	$10.00	298.41%	Buy
IMMX	Immix Biopharma	$2.29	$7.00	205.68%	Buy
PALI	Palisade Bio	$1.90	$1.50	-21.05%	Buy

CARM Forecast FAQ

Is Carisma Therapeutics a good buy?

Yes, according to 3 Wall Street analysts, Carisma Therapeutics (CARM) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of CARM's total ratings.

What is CARM's price target?

Carisma Therapeutics (CARM) average price target is $6 with a range of $6 to $6, implying a 1335.75% from its last price of $0.418. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Carisma Therapeutics stock go up soon?

According to Wall Street analysts' prediction for CARM stock, the company can go up by 1335.75% (from the last price of $0.418 to the average price target of $6), up by 1335.75% based on the highest stock price target, and up by 1335.75% based on the lowest stock price target.

Can Carisma Therapeutics stock reach $1?

CARM's average twelve months analyst stock price target of $6 supports the claim that Carisma Therapeutics can reach $1 in the near future.

What are Carisma Therapeutics's analysts' financial forecasts?

Carisma Therapeutics's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $24.13M (high $29.95M, low $19.12M), average EBITDA is $-14.477M (high $-11.473M, low $-17.968M), average net income is $-23.971M (high $-17.504M, low $-31.487M), average SG&A $19.34M (high $24M, low $15.33M), and average EPS is $-0.577 (high $-0.421, low $-0.758). CARM's analysts financial forecasts for the fiscal year (Dec 2028) are as follows: average revenue is $29.48M (high $36.59M, low $23.36M), average EBITDA is $-17.689M (high $-14.018M, low $-21.955M), average net income is $-23.701M (high $-17.307M, low $-31.131M), average SG&A $23.63M (high $29.33M, low $18.73M), and average EPS is $-0.571 (high $-0.417, low $-0.749).

Did the CARM's actual financial results beat the analysts' financial forecasts?

Based on Carisma Therapeutics's last annual report (Dec 2023), the company's revenue was $14.92M, beating the average analysts forecast of $8.91M by 67.53%. Apple's EBITDA was $-86.879M, beating the average prediction of $-5.343M by 1525.96%. The company's net income was $-86.879M, missing the average estimation of $-108M by -19.85%. Apple's SG&A was $29.52M, beating the average forecast of $7.14M by 313.66%. Lastly, the company's EPS was $-259, beating the average prediction of $-2.609 by 9832.28%. In terms of the last quarterly report (Sep 2023), Carisma Therapeutics's revenue was $3.83M, beating the average analysts' forecast of $1.19M by 222.50%. The company's EBITDA was $-22.344M, beating the average prediction of $-712K by 3038.20%. Carisma Therapeutics's net income was $-21.403M, missing the average estimation of $-23.68M by -9.62%. The company's SG&A was $6.62M, beating the average forecast of $951.09K by 596.04%. Lastly, the company's EPS was $-0.53, missing the average prediction of $-0.57 by -7.02%